Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crefmirlimab - ImaginAb Inc

Drug Profile

Crefmirlimab - ImaginAb Inc

Alternative Names: 89-Zr CD8 ImmunoPET minibody - ImaginAb Inc; 89Zr CD8 Immuno-PET agent - ImaginAb; 89Zr-crefmirlimab berdoxam - ImaginAb; 89Zr-Df-crefmirlimab - ImaginAb; 89Zr-Df-IAB22M2C - ImaginAb; [89Zr]-Df-Crefmirlimab; [89Zr]Df-IAB22M2C; CD8 T cell I/O imaging agent; CD8 T Cell imaging agent; CD8-ImmunoPET; IAB 22 M2C; Minibody CD8 T Cell imaging agent; Zirconium 89Zr crefmirlimab berdoxam; Zr-89 IAB22M2C

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImaginAb Inc
  • Class Antibody diagnostics; Antineoplastics; Diagnostic agents; Imaging agents; Immunoconjugates; Immunoglobulin fragments; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma; Renal cell carcinoma
  • Phase II Inclusion body myositis; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours
  • No development reported Cervical cancer; Gastric cancer; Graft-versus-host disease

Most Recent Events

  • 25 Jan 2024 Interim pharmacokinetics data from a phase II in solid tumours presented at the 2024 Genitourinary Cancers Symposium (ASCO-GSC-2024)
  • 02 Jun 2023 Efficacy data from phase II trial for Solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 12 May 2023 National Institute of Neurological Disorders and Stroke plans a phase I trial in Multiple sclerosis and Leukoencephalopathy (Diagnosis) (IV) in the US in May 2023 (NCT05849467)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top